Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines
暂无分享,去创建一个
Tom H. M. Ottenhoff | Hazel M. Dockrell | F. Mascart | H. Dockrell | T. Ottenhoff | H. McShane | Steven G. Smith | F. Dieli | H. Fletcher | K. V. van Meijgaarden | Helen McShane | S. Joosten | N. Caccamo | Francesco Dieli | Helen A. Fletcher | Kaatje Smits | Simone A. Joosten | Krista E. van Meijgaarden | Iman Satti | Nadia Caccamo | Francoise Mascart | Kaatje Smits | I. Satti
[1] D. Chauhan,et al. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. , 2008, Vaccine.
[2] R. Coler,et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys , 2009, Proceedings of the National Academy of Sciences.
[3] M. Altfeld,et al. Standardization of cytokine flow cytometry assays , 2005, BMC Immunology.
[4] P. Defechereux,et al. Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization , 2009, Clinical and Vaccine Immunology.
[5] C. Locht,et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. , 2002, The Journal of infectious diseases.
[6] Joan Costa,et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. , 2010, Vaccine.
[7] M. Roederer,et al. Optimizing a multicolor immunophenotyping assay. , 2007, Clinics in laboratory medicine.
[8] G. Kaplan,et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. , 2010, American journal of respiratory and critical care medicine.
[9] Mario Roederer,et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.
[10] D. Sherman,et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. , 2012, The Journal of clinical investigation.
[11] B. Gicquel,et al. Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. , 2009, Vaccine.
[12] K. Stagliano,et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. , 2010, Vaccine.
[13] M. Salmon,et al. The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. , 2008, The Journal of clinical investigation.
[14] P. Andersen,et al. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. , 2014, Vaccine.
[15] T. van der Poll,et al. Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon , 2007, Infection and Immunity.
[16] R. Koup,et al. Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations , 2007, European journal of immunology.
[17] P. Haslett,et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. , 2004, Journal of immunological methods.
[18] P. Klenerman,et al. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming , 2009, Immunology.
[19] G. Kaplan,et al. Bacillus Calmette-Guérin Vaccination of Human Newborns Induces T Cells with Complex Cytokine and Phenotypic Profiles1 , 2008, The Journal of Immunology.
[20] Z. Xing,et al. Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1 , 2004, The Journal of Immunology.
[21] H. Maecker,et al. A Model for Harmonizing Flow Cytometry in Clinical Trials , 2022 .
[22] D. Cavalieri,et al. Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion. , 2012, Immunity.
[23] J. Christensen,et al. CD4 and CD8 T Cell Responses to the M. tuberculosis Ag85B-TB10.4 Promoted by Adjuvanted Subunit, Adenovector or Heterologous Prime Boost Vaccination , 2009, PloS one.
[24] R. Davies,et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. , 2009, American journal of respiratory and critical care medicine.
[25] M. Roederer,et al. T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.
[26] H. Dockrell,et al. Whole blood assays for interferon-gamma: practicalities and potential for use as diagnostic tests in the field. , 2000, Leprosy review.
[27] M Roederer,et al. T cell assays and MIATA: the essential minimum for maximum impact. , 2012, Immunity.
[28] Tom H. M. Ottenhoff,et al. Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis , 2009, PloS one.
[29] H. Dockrell,et al. A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. , 2008, Tuberculosis.
[30] J. Dietrich,et al. Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose , 2009, PloS one.
[31] M. Roederer. How many events is enough? Are you positive? , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[32] M. Jaimes,et al. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI) , 2013, Cytometry Part A.
[33] C. F. von Reyn,et al. Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine , 2010, AIDS.
[34] C. Locht,et al. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. , 2013, Vaccine.
[35] R. Koup,et al. Intracellular cytokine optimization and standard operating procedure , 2006, Nature Protocols.
[36] V. Maino,et al. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. , 1998, Journal of immunology.
[37] H. McShane,et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial , 2014, The Lancet. Infectious diseases.
[38] S. Kaufmann,et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. , 2005, The Journal of clinical investigation.
[39] T. Ottenhoff,et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. , 2010, Vaccine.
[40] T. Scriba,et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. , 2009, Vaccine.
[41] Laurie Lamoreaux,et al. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. , 2006, Journal of immunological methods.
[42] M. Demoitié,et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. , 2013, American journal of respiratory and critical care medicine.